Eisai, BMS to develop antibody-drug conjugate for solid tumors

By The Science Advisory Board staff writers

June 18, 2021 -- Eisai and Bristol Myers Squibb (BMS) have entered a global strategic collaboration to develop and commercialize MORAb-202, an antibody-drug conjugate.

MORAb-202 is Eisai's first antibody drug conjugate and combines the company's in-house-developed antifolate receptor alpha antibody with its anticancer agent eribulin, using an enzyme-cleavable linker. The payload eribulin, known as Halaven, is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action.

The two companies will jointly develop and commercialize MORAb-202 in the following areas: Japan, China, countries in the Asia-Pacific region, the U.S., Canada, Europe (including the European Union and the U.K.), and Russia.

BMS will be responsible for developing and commercializing the drug in regions outside of the collaboration territories. Eisai will remain responsible for the manufacturing and supply of MORAb-202 globally.

Under the collaboration, BMS will pay $650 million to Eisai, including $200 million as payment toward Eisai research and development expenses. Eisai is also entitled to receive up to $2.5 billion in potential future development, regulatory, and commercial milestones.

The companies will share profits, research and development, and commercialization costs in the collaboration territories. BMS will also pay Eisai a royalty on sales outside of the collaboration territories.

Evotec, BMS debut program to speed academic translational research
Evotec announced on May 6 a new program that aims to accelerate translational research from the U.K.'s academic life science ecosystem in collaboration...
Molecular Templates, BMS to develop engineered toxin body therapies
Molecular Templates has entered into a worldwide strategic research collaboration with Bristol Myers Squibb (BMS) to discover and develop multiple novel...
BMS licenses SARS-CoV-2 neutralizing mAb combo
Bristol Myers Squibb (BMS) has entered into an agreement with Rockefeller University to license a SARS-CoV-2 neutralizing monoclonal antibody (mAb) combination.
ArsenalBio, Bristol Myers Squibb to develop cell therapies for solid tumors
ArsenalBio has formed a multiyear discovery collaboration with Bristol Myers Squibb to advance next-generation T-cell therapies for the treatment of solid...
Insitro, Bristol Myers Squibb collaborate on novel treatments
Insitro has entered into a five-year agreement with Bristol Myers Squibb for the discovery and development of novel therapies for the treatment of amyotrophic...

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter